The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

[1]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[2]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[3]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[4]  David H. Miller,et al.  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis , 2005, Multiple sclerosis.

[5]  X. Montalban,et al.  Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.

[6]  M Hutchinson,et al.  Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.

[7]  H. Tremlett.  Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects , 2005, Neurology.

[8]  G. Cutter,et al.  Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis , 2003, Multiple sclerosis.

[9]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[10]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[11]  D. Jeffery.  Early intervention with immunomodulatory agents in the treatment of multiple sclerosis , 2002, Journal of the Neurological Sciences.

[12]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[13]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[14]  A. Thompson,et al.  The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results , 2001, Multiple sclerosis.

[15]  T. Scott,et al.  Short-term prognosis in early relapsing-remitting multiple sclerosis , 2000, Neurology.

[16]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[17]  Jacqueline Palace,et al.  The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.

[18]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[19]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[20]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[21]  C. ffrench-Constant,et al.  Pathogenesis of multiple sclerosis , 1994, The Lancet.

[22]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[23]  C. Janeway,et al.  Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma , 1993, The Journal of experimental medicine.

[24]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[25]  T. Carlos,et al.  Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. , 1990, Blood.

[26]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[27]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[28]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[29]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.